Stay updated on Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.

Latest updates to the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page
- Check3 days agoChange Detected- Revision updated from v3.0.1 to v3.0.2; removed the Back to Top link.SummaryDifference0.1%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.1%
- Check17 days agoChange DetectedThe webpage has undergone significant updates, including the addition of numerous specific locations and facility names across various countries, as well as the introduction of new medical terms related to drug safety and thyroid cancer. Notably, the previous version's references to certain locations and terms have been removed.SummaryDifference21%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check46 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.8%
Stay in the know with updates to Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.